Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon

Arthritis Care and Research

Volumn 64, Issue 6, 2012, Pages 925-929

  Fava, Andrea ^a   Wung, Peter K ^a   Wigley, Fredrick M ^a   Hummers, Laura K ^a   Daya, Natalie R ^b   Ghazarian, Sharon R ^a   Boin, Francesco ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; PLACEBO; VASODILATOR AGENT; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; RHO KINASE;

ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; CLINICAL ARTICLE; COLD SENSITIVITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGITAL ARTERY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; LOW TEMPERATURE; MALE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; SKIN TEMPERATURE; SYSTEMIC SCLEROSIS; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SKIN; TREATMENT OUTCOME; VASCULARIZATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADMINISTRATION, ORAL; ADULT; AGED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; RHO-ASSOCIATED KINASES; SCLERODERMA, SYSTEMIC; SKIN; SKIN TEMPERATURE; TREATMENT OUTCOME;

EID: 84863202226     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21622     Document Type: Article

References (15)

1. Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005;17:752-60.
2. Ekenvall L, Lindblad LE, Norbeck O, Etzell BM. Alphaadrenoceptors and cold-induced vasoconstriction in human finger skin. Am J Physiol 1988;255:H1000-3.
3. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent α (2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000;278:H1075-83.
4. Flavahan NA, Flavahan S, Liu Q, Wu S, Tidmore W, Wiener CM, et al. Increased a2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000;43:1886-90.
5. Wise RA, Wigley FM, White B, Leatherman G, Zhong J, Krasa H, et al. Efficacy and tolerability of a selective a2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebocontrolled, randomized crossover study. Arthritis Rheum 2004;50:3994-4001.
6. Bailey SR, Eid AH, Mitra S, Flavahan S, Flavahan NA. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004;94:1367-74.
7. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E, for the Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebocontrolled double-blind trial. J Neurol Sci 2005;238:31-9.
8. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol 2005;46:1803-11.
9. Ishikura K, Yamada N, Ito M, Ota S, Nakamura M, Isaka N, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174-8.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
11. Wollersheim H, Thien T, van't Laar A. Nifedipine in primary Raynaud's phenomenon and in scleroderma: oral versus sublingual hemodynamic effects. J Clin Pharmacol 1987;27:907-13.
12. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rhokinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57-62.
13. Yada T, Shimokawa H, Hiramatsu O, Kajita T, Shigeto F, Tanaka E, et al. Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol 2005;45:599-607.
14. Zhou H, Zhang KX, Li YJ, Guo BY, Wang M. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses high glucose-induced proliferation and collagen synthesis in rat cardiac fibroblasts. Clin Exp Pharmacol Physiol 2011;38:387-94.
15. Hinderling PH, Karara AH, Tao B, Pawula M, Wilding I, Lu M. Systemic availability of the active metabolite hydroxy-fasudil after administration of fasudil to different sites of the human gastrointestinal tract. J Clin Pharmacol 2007;47:19-25.